TY - JOUR
T1 - Apolipoprotein E genotype does not influence the progression of multiple sclerosis
AU - Savettieri, Giovanni
AU - Andreoli, Virginia
AU - Bonavita, Simona
AU - Cittadella, Rita
AU - Caltagirone, Carlo
AU - Fazio, Maria Carolina
AU - Girlanda, Paolo
AU - Le Pira, Francesco
AU - Liguori, Maria
AU - Logroscino, Giancarlo
AU - Lugaresi, Alessandra
AU - Nocentini, Ugo
AU - Reggio, Arturo
AU - Salemi, Giuseppe
AU - Serra, Paolo
AU - Tedeschi, Gioacchino
AU - Toma, Lucia
AU - Trojano, Maria
AU - Valentino, Paola
AU - Quattrone, Aldo
PY - 2003/9/1
Y1 - 2003/9/1
N2 - Objective: To investigate the association between apolipoprotein E (APOE) polymorphisms and the progression of MS. Methods: We investigated 428 subjects affected by clinically defined MS, with a disease duration of at least three years. We collected data concerning the age at onset of MS, clinical type, disease duration and disability according to the expanded disability status scale (EDSS). We also calculated the progression index (PI) to evaluate disease progression. APOE genotyping and the -491 A/T polymorphism of the APOE promoter were determined. Results: No association was observed between the APOE ε4 allele and clinical characteristics of our study population. We also investigated the -491 A/T APOE promoter polymorphism in 236 MS subjects and did not find any association between the -491 A/T polymorphism and the selected clinical variables. Conclusions: In our population the APOE ε4 allele and the -491 A/T APOE promoter polymorphism are not associated with a more rapid course of MS.
AB - Objective: To investigate the association between apolipoprotein E (APOE) polymorphisms and the progression of MS. Methods: We investigated 428 subjects affected by clinically defined MS, with a disease duration of at least three years. We collected data concerning the age at onset of MS, clinical type, disease duration and disability according to the expanded disability status scale (EDSS). We also calculated the progression index (PI) to evaluate disease progression. APOE genotyping and the -491 A/T polymorphism of the APOE promoter were determined. Results: No association was observed between the APOE ε4 allele and clinical characteristics of our study population. We also investigated the -491 A/T APOE promoter polymorphism in 236 MS subjects and did not find any association between the -491 A/T polymorphism and the selected clinical variables. Conclusions: In our population the APOE ε4 allele and the -491 A/T APOE promoter polymorphism are not associated with a more rapid course of MS.
KW - APOE polymorphism
KW - APOE promoter
KW - MS progression
KW - Multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=0141832048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141832048&partnerID=8YFLogxK
U2 - 10.1007/s00415-003-0163-8
DO - 10.1007/s00415-003-0163-8
M3 - Article
C2 - 14504972
AN - SCOPUS:0141832048
VL - 250
SP - 1094
EP - 1098
JO - Journal of Neurology
JF - Journal of Neurology
SN - 0340-5354
IS - 9
ER -